Autolus Therapeutics PLC
NASDAQ:AUTL

Watchlist Manager
Autolus Therapeutics PLC Logo
Autolus Therapeutics PLC
NASDAQ:AUTL
Watchlist
Price: 1.88 USD 5.62% Market Closed
Market Cap: 500.3m USD

Operating Margin
Autolus Therapeutics PLC

-901.9%
Current
-5 463%
Average
-5.3%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-901.9%
=
Operating Profit
-270m
/
Revenue
29.9m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
UK
Autolus Therapeutics PLC
NASDAQ:AUTL
500.3m USD
-902%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
364.7B USD
31%
US
Amgen Inc
NASDAQ:AMGN
157.9B USD
31%
US
Gilead Sciences Inc
NASDAQ:GILD
146.8B USD
38%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
100.1B USD
39%
AU
CSL Ltd
ASX:CSL
131.4B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
61.4B USD
29%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
59.7B USD
-7%
US
Seagen Inc
F:SGT
39.3B EUR
-33%

Autolus Therapeutics PLC
Glance View

Market Cap
500.3m USD
Industry
Biotechnology

Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. The firm is focused on developing programmed T cell therapies for the treatment of cancer. The firm has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. Its lead clinical programs include AUTO1 (obecabtagene autoleucel, Obe-Cel), AUTO4, and AUTO6 / AUTO6NG. Obe-cel is a CD19 CAR T cell investigational therapy designed to overcome limitations in clinical activity and safety. Obe-cel reduces toxicity and is less prone to T cell exhaustion, which could improve persistence and the ability of programmed T cells to engage in serial killing of target cancer cells. AUTO4 is a T cell therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1. AUTO6 / AUTO6NG is a T cell therapy targeting GD2 in development for the treatment of neuroblastoma. Its other clinical programs include AUTO5, AUTO7, and AUTO8.

AUTL Intrinsic Value
8.28 USD
Undervaluation 77%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-901.9%
=
Operating Profit
-270m
/
Revenue
29.9m
What is the Operating Margin of Autolus Therapeutics PLC?

Based on Autolus Therapeutics PLC's most recent financial statements, the company has Operating Margin of -901.9%.

Back to Top